Alzamend Neuro Income Statement

Financials in millions USD. Fiscal year is May - April.

Millions USD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan '26 Jan 31, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021
Selling, General & Admin	3.39	3.08	3.48	7.42	7.12	3.64
Research & Development	3.65	1.41	6.46	7.45	5.2	1.31
Total Operating Expenses	7.03	4.5	9.94	14.87	12.32	4.95
Operating Income	-7.03	-4.5	-9.94	-14.87	-12.32	-4.95
Interest Income	-	-	-	-	-	0
Interest Expense	-0.01	-0.02	-0.01	-0.01	-0.05	-0.16
Other Non-Operating Income (Expense)	-	-	-	-	-0	-0.06
Total Non-Operating Income (Expense)	-0.01	-0.02	-0.01	-0.01	-0.05	-0.22
Pretax Income	-7.04	-4.51	-9.95	-14.88	-12.37	-5.17
Net Income	-7.54	-5.11	-9.95	-14.88	-12.36	-5.05
Net Income Attributable to Preferred Dividends	0.03	0.59	-	-	-	-
Net Income to Common	-7.54	-5.11	-9.95	-14.88	-12.36	-5.05
Shares Outstanding (Basic)	3	0	0	0	0	0
Shares Outstanding (Diluted)	3	0	0	0	0	0
Shares Change (YoY)	767.42%	507.76%	2.68%	9.46%	22.64%	1.96%
EPS (Basic)	-3.67	-11.32	-132.33	-206.01	-189.00	-94.50
EPS (Diluted)	-3.67	-11.32	-132.33	-206.01	-189.00	-94.50
Shares Outstanding	3.8	0.78	0.08	0.07	0.07	0.05
Free Cash Flow	-6.17	-6.87	-8.42	-8.92	-6.72	-2.71
Free Cash Flow Per Share	-2.45	-15.24	-113.48	-123.53	-101.83	-50.40
EBITDA	-6.94	-4.45	-9.89	-14.85	-12.32	-4.95
EBIT	-7.03	-4.5	-9.94	-14.87	-12.32	-4.95

SEC Filings: 10-K · 10-Q